Tuesday, 5th June 2007 (4105 views)

Clinical stage nanomedicine company CytImmune Sciences claims to have presented positive data regarding the use of gold-based treatments in patients with cancer.

The phase I trial of CYT-6091 (Aurimune), was initiated to establish whether the treatment would perform in the same manner in humans as in preclinical studies and companion animals.

Aurimune is recombinant human tumour necrosis factor alpha (TNF) bound to the surface of 27 nanometer PEGylated colloidal gold nanoparticles.

By binding PEG-Thiol and TNF to the surface of colloidal, gold nanoparticles help "harness the potential of the anti-cancer agent" by making them invisible to immune detection and by targeting delivery of TNF accurately to the tumour sites.

"The next step is to safely and systemically administer doses of TNF at levels similar to the clinical experience with isolated limb perfusion where efficacy [for example] tumour regression has been observed in 85 per cent of patients treated," commented Dr. Lawrence Tamarkin, chief executive officer of CytImmune Sciences.

The doctor added that if this was successful it would represent "a significant step forward" in the advancement of cancer therapy.

CytImmune Sciences is a clinical stage nanomedicine company which aims to develop multifunctional, tumour-targeted therapies by using the "unique" properties of gold nanoparticles.

 

« Back to the stories

 

The news feeds on this site are independently provided by Adfero Limited © and do not represent the views or opinions of the World Gold Council.